PREVENTION DE LA RESISTANCE A LA RIFAMPICINE PAR LE PYRAZINAMIDE DANS LA TUBERCULOSE EXPERIMENTALE DE LA SOURIS

Translated title of the contribution: The prevention of rifampicin resistance with pyrazinamide

J. Grosset, C. Truffot-Pernot, S. Poggi

Research output: Contribution to journalArticlepeer-review

Abstract

The capacity of Pyrazinamide (PZA) to prevent the selection of Rifampicin (RMP) resistant mutants was tested by the intravenous innoculation of 160 mice with 2 x 106 c.f.u. of M. tuberculosis, and two weeks later, the treatment of the mice either with 10 mg/kg/day RMP alone or with RMP + PZA 150 mg/kg/day. After three months of treatment, lungs and spleen were culture positive in respectively 95% and 90% of the mice treated with RMP alone and in 37% and 24% of the mice treated by RMP + PZA (p < 10-5). The strains isolated from lungs and spleen were resistant to Rifampicin in respectively 87% and 75% of the mice treated with RMP alone and in none of those treated with RMP + PZA.

Translated title of the contributionThe prevention of rifampicin resistance with pyrazinamide
Original languageFrench
Pages (from-to)205-208
Number of pages4
JournalRevue des maladies respiratoires
Volume2
Issue number4
StatePublished - Jan 1 1985

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'The prevention of rifampicin resistance with pyrazinamide'. Together they form a unique fingerprint.

Cite this